Journal articles on the topic 'Hoffman-La Roche AG'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Hoffman-La Roche AG.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Pott, Christiane, Eva Hoster, Britta Kehden, Michael Unterhalt, Michael Herold, Richard van der Jagt, Ann Janssens, et al. "Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients." Blood 132, Supplement 1 (November 29, 2018): 396. http://dx.doi.org/10.1182/blood-2018-99-115930.
Full textSchmidt, Christian, Anna-Katharina Zoellner, Vindi Jurinovic, Martin Sökler, Roswitha Forstpointner, Sascha Haubner, Christian Buske, et al. "Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)." Blood 132, Supplement 1 (November 29, 2018): 448. http://dx.doi.org/10.1182/blood-2018-99-111692.
Full textBezombes, Christine, Emilie Decaup, Pauline Gravelle, Christine Jean, Camille Laurent, Christian Klein, Nathalie Varoqueaux, Ariel Savina, Jean-Jacques Fournié, and Guy Laurent. "Multicellular Aggregates Of Lymphoma Cells (MALC): An Invaluable Model For Studying Follicular Lymphoma Biology and Mechanisms Of Action Of Therapeutic Drugs Such As Anti-CD20 Antibodies." Blood 122, no. 21 (November 15, 2013): 4410. http://dx.doi.org/10.1182/blood.v122.21.4410.4410.
Full textAlig, Stefan, Alessandro Pastore, Vindi Jurinovic, Sarah Häbe, Deepak Bararia, Verena Passerini, William Keay, et al. "Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced Follicular Lymphoma: An Analysis from the GLSG2000 Trial." Blood 132, Supplement 1 (November 29, 2018): 4096. http://dx.doi.org/10.1182/blood-2018-99-118000.
Full textVersmold, Katharina, Ferras Alashkar, Carina Raiser, Richard Ofori-Asenso, Tao Xu, Yutong Liu, Pablo Katz, Aijing Shang, and Alexander Roeth. "Clinical Profile and Long-Term Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab in a Real-World Setting: High Frequency of Anemia Despite Decreased Intravascular Hemolysis." Blood 138, Supplement 1 (November 5, 2021): 4314. http://dx.doi.org/10.1182/blood-2021-147162.
Full textSeymour, John F., Thomas J. Kipps, Barbara F. Eichhorst, Peter Hillmen, James D'Rozario, Sarit Assouline, Carolyn Owen, et al. "Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)." Blood 134, Supplement_1 (November 13, 2019): 355. http://dx.doi.org/10.1182/blood-2019-123930.
Full textPhillips, Tycel J., Adam J. Olszewski, Javier Munoz, Tae Min Kim, Dok Hyun Yoon, Richard Greil, Jason Westin, et al. "Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma." Blood 136, Supplement 1 (November 5, 2020): 37–38. http://dx.doi.org/10.1182/blood-2020-136295.
Full textZeng, Zhihong, Natalia Baran, Sergej Konoplev, Antonio Cavazos, Qi Zhang, Vinitha Mary Kuruvilla, Philip Lorenzi, et al. "Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and in Vivo." Blood 134, Supplement_1 (November 13, 2019): 3911. http://dx.doi.org/10.1182/blood-2019-125469.
Full textSchuster, Michael W., Miguel A. Canales, Jason Westin, Josée M. Zijlstra, George A. Follows, Reem Karmali, Nagesh Kalakonda, et al. "Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study." Blood 136, Supplement 1 (November 5, 2020): 34–35. http://dx.doi.org/10.1182/blood-2020-137025.
Full textThom, Howard Z., Jason Shafrin, Edna Keeney, Lauren M. Zhao, George J. Joseph, Menaka Bhor, Avery A. Rizio, Lanetta Bronté-Hall, and Nirmish Shah. "Relationship between Vaso-Occlusive Crisis and Quality of Life: An Analysis of Patients with Sickle Cell Disease in the United States." Blood 134, Supplement_1 (November 13, 2019): 4700. http://dx.doi.org/10.1182/blood-2019-124132.
Full textJaeger, Ulrich, Michael R. Bishop, Gilles Salles, Stephen J. Schuster, Richard T. Maziarz, Xia Han, Alexander Savchenko, et al. "Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial." Blood 136, Supplement 1 (November 5, 2020): 48–49. http://dx.doi.org/10.1182/blood-2020-137045.
Full textSimpson, Ewurabena, Robert J. Klaassen, Pranesh Chakraborty, Beth Potter, Melanie Ann Kirby-Allen, Isaac Odame, Suzan Williams, et al. "Increasing Incidence and Prevalence of Pathologic Hemoglobinopathies Among Children in Ontario, Canada from 1991-2013." Blood 132, Supplement 1 (November 29, 2018): 4698. http://dx.doi.org/10.1182/blood-2018-99-110468.
Full textShafrin, Jason, Howard Z. Thom, Daisy Gaunt, Lauren M. Zhao, George J. Joseph, Menaka Bhor, Avery A. Rizio, Lanetta Bronté-Hall, and Nirmish Shah. "How Does Sickle Cell Disease Severity Affect Patient Collection of Disability Insurance and Income: An Analysis of US Survey Data." Blood 134, Supplement_1 (November 13, 2019): 5781. http://dx.doi.org/10.1182/blood-2019-122774.
Full textSchuster, Michael W., Miguel A. Canales, Jason Westin, Josée M. Zijlstra, George A. Follows, Reem Karmali, Nagesh Kalakonda, et al. "Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study." Blood 136, Supplement 1 (November 5, 2020): 5–6. http://dx.doi.org/10.1182/blood-2020-137020.
Full textAl-Sawaf, Othman, Can Zhang, Sandra Robrecht, Anna-Maria Fink, Paula Cramer, Carmen D. Herling, Julia Von Tresckow, et al. "Severe Infections in Patients with Chronic Lymphocytic Leukemia Treated with (Immuno-)Chemotherapy: A Pooled Analysis of Gcllsg Trials." Blood 136, Supplement 1 (November 5, 2020): 18–19. http://dx.doi.org/10.1182/blood-2020-139242.
Full textThieblemont, Catherine, Michael Dickinson, Joaquin Martinez-Lopez, Arne Kolstad, Jason P. Butler, Monalisa Ghosh, Leslie L. Popplewell, et al. "Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study." Blood 138, Supplement 1 (November 5, 2021): 131. http://dx.doi.org/10.1182/blood-2021-145025.
Full textIssa, Jean-Pierre, Marco Gobbi, Patricia L. Kropf, Pierre Fenaux, Gail J. Roboz, Jiri Mayer, Jürgen Krauter, et al. "Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study." Blood 134, Supplement_1 (November 13, 2019): 4235. http://dx.doi.org/10.1182/blood-2019-129614.
Full textIoannou, Nikolaos, Patrick R. Hagner, Fadi Towfic, Anita K. Gandhi, Kostas Stamatopoulos, Piers E. M. Patten, Anna Vardi, and Alan G. Ramsay. "Eliciting Anti-Tumor T Cell Immunity in Chronic Lymphocytic Leukemia (CLL) with PD-L1/PD-1 Blockade Is Enhanced By Avadomide Immunotherapy through the Triggering of Immunogenic Interferon Signaling." Blood 132, Supplement 1 (November 29, 2018): 237. http://dx.doi.org/10.1182/blood-2018-99-111605.
Full textRoboz, Gail J., Hartmut Döhner, Marco Gobbi, Patricia L. Kropf, Jiri Mayer, Jürgen Krauter, Tadeusz Robak, et al. "Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles." Blood 134, Supplement_1 (November 13, 2019): 2591. http://dx.doi.org/10.1182/blood-2019-127253.
Full textVarughese, Nisha S., Alex Wong, Robert J. Klaassen, Elaine W. Leung, Kathryn Elizabeth Webert, Sylvain Grenier, Sarah Jennings, et al. "Pharmacist Integration into the Hemophilia Treatment Centre: A Canadian Pilot Project to Optimize Treatment and Improve Cost-Savings Using Pharmacokinetic Assessments of Hemophilia Patients." Blood 138, Supplement 1 (November 5, 2021): 832. http://dx.doi.org/10.1182/blood-2021-147813.
Full textOkwor, Chisom Ifeoma, Robert J. Klaassen, Mary-Ann Harrison, Ken Tang, Isabelle Laforest, Brooke Bowerman, and Ewurabena Simpson. "Predictors of Hydroxyurea Use in Children with Sickle Cell Disease." Blood 132, Supplement 1 (November 29, 2018): 4934. http://dx.doi.org/10.1182/blood-2018-99-111377.
Full textSiddiqi, Tanya, Ulrich Jaeger, Olga Moshkovich, Jennifer Devlen, Matthew Miera, Agnes Williams, Jens Hasskarl, Fei Fei Liu, Julia Braverman, and Gilles Salles. "Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy." Blood 136, Supplement 1 (November 5, 2020): 22–23. http://dx.doi.org/10.1182/blood-2020-137656.
Full textBücklein, Veit, Thomas Köhnke, Frauke Schnorfeil, Klaus H. Metzeler, Nikola P. Konstandin, Annika Maria Dufour, Cristina Sauerland, Wolfgang Hiddemann, Karsten Spiekermann, and Marion Subklewe. "Minimal Residual Disease (MRD) Detection By Flow Cytometry Complements Molecular MRD Assessment in AML." Blood 132, Supplement 1 (November 29, 2018): 2753. http://dx.doi.org/10.1182/blood-2018-99-119065.
Full textBlair, Joanne, Andrew McKay, Colin Ridyard, Keith Thornborough, Emma Bedson, Matthew Peak, Mohammed Didi, et al. "Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT." Health Technology Assessment 22, no. 42 (August 2018): 1–112. http://dx.doi.org/10.3310/hta22420.
Full textLivingston, Joel, Melanie Jackson, Ziyad Alrajihi, Catherine McGuire, Robert J. Klaassen, and Melanie Kirby -Allen. "Evaluating the Impact of Thrombopoietin Receptor Agonists Medications on Patient Outcomes and Quality of Life in Pediatric Immune Thrombocytopenia." Blood 138, Supplement 1 (November 5, 2021): 4072. http://dx.doi.org/10.1182/blood-2021-146031.
Full textFerreri, Andrés J. M., Kate Cwynarski, Elisa Jacobsen Pulczynski, Christopher P. Fox, Elisabeth Schorb, Paul La Rosée, Mascha Binder, et al. "Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial." Blood 128, no. 22 (December 2, 2016): 511. http://dx.doi.org/10.1182/blood.v128.22.511.511.
Full textAhaneku, Hycienth O., Hagop M. Kantarjian, Graciela M. Nogueras González, Gautam M. Borthakur, Srdan Verstovsek, Tapan M. Kadia, Naveen Pemmaraju, et al. "Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet." Blood 134, Supplement_1 (November 13, 2019): 2930. http://dx.doi.org/10.1182/blood-2019-129108.
Full textKadia, Tapan M., Gautam M. Borthakur, Elias Jabbour, Marina Y. Konopleva, Farhad Ravandi, Courtney D. DiNardo, Daniella Zheleva, David Blake, and Judy H. Chiao. "An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS." Blood 134, Supplement_1 (November 13, 2019): 3926. http://dx.doi.org/10.1182/blood-2019-131930.
Full textGuerra, Veronica A., Yan Yuanqing, Joanne Hsu, Feng Wang, Mansour Alfayez, Kiyomi Morita, Xingzhi Song, et al. "Comprehensive Analysis of Genotype and Prior Exposures in Therapy-Related Myeloid Neoplasms (t-MNs)." Blood 134, Supplement_1 (November 13, 2019): 458. http://dx.doi.org/10.1182/blood-2019-127498.
Full textPereira-Martins, Diego A., Juan L. Coelho-Silva, Isabel Weinhäuser, Luisa C. A. Koury, Raul Antônio Morais Melo, Rosane Bittencourt, Katia B. Pagnano, et al. "Arsenic Trioxide Abrogate MN1 Mediated RA-Resistance in Acute Promyelocytic Leukemia." Blood 134, Supplement_1 (November 13, 2019): 5166. http://dx.doi.org/10.1182/blood-2019-131595.
Full textRichard-Carpentier, Guillaume, Hagop M. Kantarjian, Guilin Tang, C. Cameron Yin, Joseph D. Khoury, Ghayas C. Issa, Nitin Jain, et al. "Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement." Blood 134, Supplement_1 (November 13, 2019): 2582. http://dx.doi.org/10.1182/blood-2019-130864.
Full textGuerra, Veronica A., Jan A. Burger, Gautam M. Borthakur, Elias Jabbour, Naveen Pemmaraju, Tapan M. Kadia, Guillermo Garcia-Manero, Hagop M. Kantarjian, Marina Y. Konopleva, and Courtney D. DiNardo. "Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)." Blood 134, Supplement_1 (November 13, 2019): 567. http://dx.doi.org/10.1182/blood-2019-125970.
Full textCortes, Jorge, Guillermo Garcia-Manero, Koji Sasaki, Kiran Naqvi, Yesid Alvarado, Tapan M. Kadia, Farhad Ravandi, et al. "Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)." Blood 134, Supplement_1 (November 13, 2019): 1726. http://dx.doi.org/10.1182/blood-2019-126005.
Full textSasaki, Koji, Hagop M. Kantarjian, Elias Jabbour, Farhad Ravandi, Marina Y. Konopleva, Gautam M. Borthakur, William G. Wierda, et al. "The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)." Blood 134, Supplement_1 (November 13, 2019): 1642. http://dx.doi.org/10.1182/blood-2019-130148.
Full textRausch, Caitlin R., Courtney D. DiNardo, Abhishek Maiti, Nadya Jammal, Tapan M. Kadia, Kayleigh Marx, Gautam M. Borthakur, et al. "Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia." Blood 134, Supplement_1 (November 13, 2019): 2640. http://dx.doi.org/10.1182/blood-2019-131988.
Full textMontalban Bravo, Guillermo, Rashmi Kanagal-Shamanna, Koji Sasaki, Farhad Ravandi, Jorge E. Cortes, Naval G. Daver, Koichi Takahashi, et al. "Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy." Blood 134, Supplement_1 (November 13, 2019): 1312. http://dx.doi.org/10.1182/blood-2019-131998.
Full textMaiti, Abhishek, Hagop M. Kantarjian, Guillermo Garcia-Manero, Marina Y. Konopleva, Srdan Verstovsek, Michael Andreeff, Gautam M. Borthakur, et al. "Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy." Blood 134, Supplement_1 (November 13, 2019): 2641. http://dx.doi.org/10.1182/blood-2019-129621.
Full textPemmaraju, Naveen, Bing Z. Carter, Hagop M. Kantarjian, Jorge E. Cortes, Prithviraj Bose, Tapan M. Kadia, Guillermo Garcia-Manero, et al. "Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis." Blood 134, Supplement_1 (November 13, 2019): 555. http://dx.doi.org/10.1182/blood-2019-130046.
Full textJain, Nitin, Michael J. Keating, Philip A. Thompson, Jan A. Burger, Alessandra Ferrajoli, Zeev E. Estrov, Gautam M. Borthakur, et al. "Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)." Blood 134, Supplement_1 (November 13, 2019): 359. http://dx.doi.org/10.1182/blood-2019-131732.
Full textJain, Nitin, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jan A. Burger, Gautam M. Borthakur, Koichi Takahashi, et al. "Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)." Blood 134, Supplement_1 (November 13, 2019): 34. http://dx.doi.org/10.1182/blood-2019-131847.
Full textKadia, Tapan M., Jorge E. Cortes, Marina Y. Konopleva, Gautam M. Borthakur, Naveen Pemmaraju, Naval G. Daver, Guillermo Montalban Bravo, et al. "Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)." Blood 134, Supplement_1 (November 13, 2019): 2647. http://dx.doi.org/10.1182/blood-2019-122477.
Full textShort, Nicholas J., Hind Rafei, Naval G. Daver, Hyunsoo Hwang, Jing Ning, Jorge E. Cortes, Jeffrey L. Jorgensen, et al. "Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy." Blood 134, Supplement_1 (November 13, 2019): 735. http://dx.doi.org/10.1182/blood-2019-122779.
Full textCortes, Jorge, Mansour Alfayez, Tapan M. Kadia, Marina Y. Konopleva, Farhad Ravandi, Jorge E. Cortes, Elias Jabbour, et al. "Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm)." Blood 134, Supplement_1 (November 13, 2019): 1447. http://dx.doi.org/10.1182/blood-2019-127257.
Full textMontalban-Bravo, Guillermo, Rashmi Kanagal-Shamanna, Koji Sasaki, Farhad Ravandi, Jorge E. Cortes, Naval G. Daver, Koichi Takahashi, et al. "Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplastic Are Dependent on Diagnostic Criteria and Therapy." Blood 134, Supplement_1 (November 13, 2019): 647. http://dx.doi.org/10.1182/blood-2019-129373.
Full textGuerra, Veronica A., Hagop M. Kantarjian, Jorge E. Cortes, Guillermo Garcia-Manero, Lucia Masarova, Naveen Pemmaraju, Elias Jabbour, et al. "A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)." Blood 134, Supplement_1 (November 13, 2019): 4237. http://dx.doi.org/10.1182/blood-2019-125974.
Full textMontalban-Bravo, Guillermo, Rashmi Kanagal-Shamanna, Christopher B. Benton, Caleb Class, Kelly S. Chien, Koji Sasaki, Kiran Naqvi, et al. "Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes." Blood 134, Supplement_1 (November 13, 2019): 1711. http://dx.doi.org/10.1182/blood-2019-124978.
Full textRichard-Carpentier, Guillaume, Hagop M. Kantarjian, Jeffrey L. Jorgensen, Sa A. Wang, Joseph D. Khoury, Farhad Ravandi, Nicholas J. Short, et al. "Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)." Blood 134, Supplement_1 (November 13, 2019): 1299. http://dx.doi.org/10.1182/blood-2019-130283.
Full textSamra, Bachar, Hagop M. Kantarjian, Koji Sasaki, Nicholas J. Short, Rita Khouri, Joseph D. Khoury, Richard E. Champlin, et al. "Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)." Blood 134, Supplement_1 (November 13, 2019): 287. http://dx.doi.org/10.1182/blood-2019-127516.
Full textShort, Nicholas J., Hagop M. Kantarjian, Farhad Ravandi, Xuelin Huang, Nitin Jain, Koji Sasaki, Rita Khouri, et al. "Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia." Blood 134, Supplement_1 (November 13, 2019): 823. http://dx.doi.org/10.1182/blood-2019-125136.
Full textRamos Perez, Jorge M., Tapan M. Kadia, Guillermo Montalban-Bravo, Christopher B. Benton, Stefan Faderl, Koji Sasaki, Kiran Naqvi, et al. "Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)." Blood 134, Supplement_1 (November 13, 2019): 2642. http://dx.doi.org/10.1182/blood-2019-129137.
Full text